NIH Greenlights Human Trial for Kratom Compound in Opioid Treatment Research

The National Institutes of Health has received FDA clearance to begin a Phase I clinical trial for mitragynine, a compound derived from kratom. This study will assess the safety and tolerability of the substance as a potential therapeutic option for opioid use disorder. This development marks a step forward in exploring new treatments for this public health challenge.